Sinus rhythm restoration and treatment success: Insight from recent clinical trials

Clinical Cardiology

Volumn 34, Issue 1, 2011, Pages 12-22

  Saliba, Walid ^a   Wazni, Oussama M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZIMILIDE; BENZOFURAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARIPORIDE; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; MORACIZINE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; ROTIGAPTIDE; SELODENOSON; SOTALOL; TECADENOSON; TEDISAMIL; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT;

ABLATION THERAPY; BRADYCARDIA; BRONCHOSPASM; CARDIOVERSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DAILY LIFE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; EXERCISE; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; MAINTENANCE DRUG DOSE; PHOTOSENSITIVITY; POLYNEUROPATHY; QT PROLONGATION; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; THYROID DISEASE; TORSADE DES POINTES; TREATMENT OUTCOME; URINE RETENTION; XEROSTOMIA;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; ELECTRIC COUNTERSHOCK; EVIDENCE-BASED MEDICINE; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; RECURRENCE; TREATMENT OUTCOME;

EID: 79251557807     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20826     Document Type: Review

References (70)

1. Falk RH., Atrial fibrillation. N Engl J Med. 2001; 344: 1067-1078.
2. Wolf PA, Abbott RD, Kannel WB., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-988.
3. Centers for Disease Control and Prevention. Atrial fibrillation fact sheet. Accessed September 30, 2010.
4. Crijns HJ., Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs. 2005; 65: 1651-1667.
5. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, et al. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis. 2005; 48: 153-168.
6. Moe GK, Rheinboldt WC, Abildskov JA., A computer model of atrial fibrillation. Am Heart J. 1964; 67: 200-220.
7. Everett TH IV, Olgin JE., Basic mechanisms of atrial fibrillation. Cardiol Clin. 2004; 22: 9-20.
8. Van Gelder IC, Hemels ME., The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace. 2006; 8: 943-949.
9. Manios EG, Kanoupakis EM, Chlouverakis GI, et al. Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence. Cardiovasc Res. 2000; 47: 244-253.
10. Brundel BJ, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation. 2001; 103: 684-690.
11. Allessie M, Ausma J, Schotten U., Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002; 54: 230-246.
12. Nattel S., New ideas about atrial fibrillation 50 years on. Nature. 2002; 415: 219-226.
13. Shiroshita-Takeshita A, Brundel BJ, Nattel S., Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005; 13: 181-193. (Pubitemid 41372065)
14. Corradi D, Callegari S, Benussi S, et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch. 2004; 445: 498-505.
15. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004; 90: 400-405.
16. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004; 109: 363-368.
17. Nakano Y, Niida S, Dote K, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004; 43: 818-825.
18. Cha YM, Redfield MM, Shen WK, et al. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation. 2004; 109: 2839-2843.
19. Brundel BJ, Henning RH, Kampinga HH, et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res. 2002; 54: 315-324.
20. Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007; 18: 9-14.
21. Schotten U, Greiser M, Benke D, et al. Atrial fibrillation-induced atrial contractile dysfunction: a tachycardiomyopathy of a different sort. Cardiovasc Res. 2002; 53: 192-201.
22. Wyse DG., Pharmacologic approaches to rhythm versus rate control in atrial fibrillation-where are we now? Int J Cardiol 2006; 110: 301-312.
23. Singh BN., Atrial fibrillation: the rate or rhythm controversy can it be resolved on the basis of clinical trial data? J Cardiovasc Pharmacol Ther. 2005; 10: 81-83.
24. Wyse DG., Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis. 2005; 48: 125-138.
25. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825-1833.
26. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) Study. Chest. 2004; 126: 476-486.
27. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347: 1834-1840.
28. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003; 41: 1690-1696.
29. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003; 91: 15D-26D.
30. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004; 109: 1509-1513.
31. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004; 109: 1973-1980.
32. Curtis AB, Gersh BJ, Corley SD, et al. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149: 645-649.
33. Deedwania PC, Singh BN, Ellenbogen K, et al; The Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998; 98: 2574-2579.
34. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. Circulation. 2001; 104: 292-296.
35. Vora A, Karnad D, Goyal V, et al. Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. J Cardiovasc Pharmacol Ther. 2004; 9: 65-73. (Pubitemid 39071591)
36. Connolly SJ., Crijns HJGM, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009; 120: 1174-1180.
37. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation [published correction appears in N Engl J Med. 2009;360:2487]. N Engl J Med. 2009; 360: 668-678.
38. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003; 24: 1481-1487.
39. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357: 987-999.
40. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study. Am Heart J. 2008; 156: 527.e1-527.e9.
41. Kathofer S, Thomas D, Karle CA., The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 2005; 23: 217-230.
42. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358: 2678-2687.
43. Hagens VE, Van Veldhuisen DJ, Kamp O, et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm. 2005; 2: 19-24. (Pubitemid 40104304)
44. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004; 351: 2373-2383.
45. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352: 1861-1872.
46. Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol. 2006; 48: 721-730.
47. Hohnloser SH, Kuck KH, Lilienthal J., Rhythm or rate control in atrial fibrillation Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000; 356: 1789-1794.
48. Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996; 94: 1585-1591.
49. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004; 43: 241-247.
50. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002; 143: 984-990.
51. Brignole M, Menozzi C, Gasparini M, et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J. 2002; 23: 892-900.
52. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659-666.
53. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace. 2007; 9: 335-379.
54. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006; 27: 1979-2030. (Pubitemid 44313588)
55. Calkins H., New ACC/AHA/ESC guidelines for the management of atrial fibrillation: highlighting stroke prevention and catheter ablation. Accessed September 30, 2010.
56. Haigney MC., Ablation should not be first-line therapy for the treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007; 5: 673-679.
57. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009; 2: 349-361.
58. Piccini JP, Lopes RD, Kong MH, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2009; 2: 626-633.
59. Reddy VY., Atrial fibrillation: unanswered questions and future directions. Med Clin North Am. 2008; 92: 237-258, xiii.
60. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005; 111: 1100-1105. (Pubitemid 40365469)
61. Erdogan A, Carlsson J, Neumann T, et al. Quality-of-life in patients with paroxysmal atrial fibrillation after catheter ablation: results of long-term follow-up. Pacing Clin Electrophysiol. 2003; 26: 678-684.
62. Chen J, Hoff PI, Erga KS, et al. A clinical study of patients with and without recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation. Pacing Clin Electrophysiol. 2005; 28 (suppl 1): S86-S89.
63. Dagres N, Varounis C, Flevari P, et al. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy: a meta-analysis of randomized trials. Am Heart J. 2009; 158: 15-20.
64. US National Institutes of Health. Ablation vs drug therapy for atrial fibrillation-pilot trial (CABANA). Accessed September 30, 2010.
65. US National Institutes of Health. Ablation versus anti-arrhythmic (AA) drug therapy for AF-pivotal trial (CABANA). Accessed September 30, 2010.
66. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000; 101: 1138-1144.
67. Joglar JA, Kowal RC., Electrical cardioversion of atrial fibrillation. Cardiol Clin. 2004; 22: 101-111.
68. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004; 351: 2384-2391.
69. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006; 166: 719-728.
70. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003; 42: 20-29.